x

Posted 12 January, 2024

Onconetix, Inc. appointed James Sapirstein as new CEO

Nasdaq:ONCO appointed new Chief Executive Officer James Sapirstein in a 8-K filed on 12 January, 2024.


  Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board's appointment of a permanent chief executive officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Onconetix, Inc.
Health Care/Life Sciences • Pharmaceuticals
Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. Its platform includes the BWV Norovirus (NoV) S&P Nanoparticle Versatile Vaccine. Bioengineering the shell (S) and protruding (P) domains of the norovirus capsid protein, polyvalent nanoparticles and polymers/oligomers provide a versatile vaccine platform with wide applications. The company was founded by Joseph Hernandez on October 26, 2018 and is headquartered in Cincinnati, OH.
Market Cap
$4.31M
View Company Details
Onconetix, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Effective as of January 10, 2024, Dr. Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors (the "Board") of Onconetix, Inc. (the "Company"). Dr. Campbell's resignation is not the result of any disagreement with the Company relating to the Company's operations, policies or practices.


The Company entered into a Release of Claims with Dr. Campbell, pursuant to which Dr. Campbell will receive a one-time severance payment of $158,333 (the "Release"). The foregoing description of the Release is qualified in its entirety by reference to the full text of the Release, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.


On January 12, 2024, the Board appointed Dr. Ralph Schiess, the Company's Chief Science Officer, to serve as the Company's Interim Chief Executive Officer. As Interim Chief Executive Officer, Dr. Schiess shall have general supervision and direction of the business and affairs of the Company.


The biographical information for Dr. Schiess disclosed in the Company's Current Report on Form 8-K filed with the SEC on December 21, 2023 is incorporated herein by reference.


No family relationships exist between Dr. Schiess and any other directors or executive officers of the Company. There are no transactions to which the Company is or was a participant and in which either Dr. Schiess has a material interest subject to disclosure under Item 404(a) of Regulation S-K.


Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board's appointment of a permanent chief executive officer. Mr. Sapirstein shall receive $40,000 per month as compensation for his services as Lead Independent Director.